On July 30, MEDBOT-B fell 5.13% in regular trading, trading at HK$19.78/share, with turnover of HK$66.10 million. The decline extends a pattern of profit-taking following the company's positive earnings alert issued on July 22.

The sell-off continues despite DBS Vickers initiating coverage with a Buy rating and a HK$29 target price on the same day. Market analysis points to the company's price-to-sales ratio of approximately 35x, significantly above global peers such as Medtronic and Stryker, creating sustained valuation pressure. The stock had surged over 10% on July 23 and 7% on July 27 after the company forecast its first-ever half-year profit of RMB 28-40 million, reversing a RMB 115 million loss year-over-year, driven by 200-230% revenue growth and Toumai surgical robot overseas revenue surging over 450%.

The broader Health Care Equipment sector also weighed on sentiment, with MICROPORT down 4.21%, LIFETECH SCI down 2.10%, and CHUNLI MEDICAL down 2.19%, amplifying selling pressure across the segment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)